Free Trial

Ambrx Biopharma (AMAM) News Today

Notice: This company has been marked as potentially delisted and may not be actively trading.
Johnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Deal
Fmr LLC Sells 449,560 Shares of Ambrx Biopharma Inc. (NYSE:AMAM)
Fmr LLC decreased its holdings in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 20.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,761,058 shares of the company's stock after selling 44
70,000 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Bought by Monashee Investment Management LLC
Monashee Investment Management LLC bought a new position in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 70,000 shares of the company's stock, valued
3 Stocks to Buy That Are Up 200% or More in 2024
Ambrx Biopharma Inc. (NYSE:AMAM) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Ambrx Biopharma Inc. (NYSE:AMAM - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned a
47,433 Shares in Ambrx Biopharma Inc. (NYSE:AMAM) Acquired by Bank of New York Mellon Corp
Bank of New York Mellon Corp purchased a new position in Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 47,433 shares of the company's stock, valued at approximately $
TD Asset Management Inc Grows Stock Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)
TD Asset Management Inc lifted its stake in Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 73.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 110,456 shares of the company's stock after purchasing an additional 46,728 share
Ambrx Biopharma Inc. (NYSE:AMAM) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Ambrx Biopharma Inc. (NYSE:AMAM - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and four have given a b
Robert W. Baird Reiterates "Neutral" Rating for Ambrx Biopharma (NYSE:AMAM)
Robert W. Baird reissued a "neutral" rating and issued a $28.00 target price on shares of Ambrx Biopharma in a research report on Tuesday.
Ambrx Biopharma (NYSE:AMAM) Rating Reiterated by JMP Securities
JMP Securities reissued a "market perform" rating on shares of Ambrx Biopharma in a report on Wednesday.
Ambrx Biopharma just downgraded at JMP Securities, here's why
Ambrx Biopharma (NYSE:AMAM) Stock Rating Reaffirmed by B. Riley
B. Riley reaffirmed a "neutral" rating and set a $28.00 price objective (up previously from $26.00) on shares of Ambrx Biopharma in a research report on Tuesday.
Johnson & Johnson: Biotech a shot in the arm for future growth? (AMAM)
Johnson & Johnson is actively shifting its strategy towards biotechnology and antibody-drug conjugates, balancing current revenue protection with future growth.
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
Ambrx Announces Sale to Johnson & Johnson
Ambrx Biopharma Inc. (NYSE:AMAM) Given Consensus Rating of "Moderate Buy" by Analysts
Ambrx Biopharma Inc. (NYSE:AMAM - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommen
Cantor Fitzgerald Reaffirms "Overweight" Rating for Ambrx Biopharma (NYSE:AMAM)
Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Ambrx Biopharma in a report on Monday.
Ambrix to Join NASDAQ Biotech Index
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Commodore Capital LP Has $52.26 Million Holdings in Ambrx Biopharma Inc. (NYSE:AMAM)
Commodore Capital LP lowered its position in shares of Ambrx Biopharma Inc. (NYSE:AMAM - Free Report) by 33.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,175,000 shares of the company's stock after
Optimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Rating
Goldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)
Analyst Ratings for Ambrx Biopharma
JMP Securities Initiates Coverage on Ambrx Biopharma (NYSE:AMAM)
JMP Securities began coverage on shares of Ambrx Biopharma in a research report on Monday. They set an "outperform" rating and a $15.00 price objective on the stock.
Get Ambrx Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter.

Buy this small stock before coming AI Tidal Wave (Ad)

The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.

Get the name and ticker symbol for free - just click here.

AMAM Media Mentions By Week

AMAM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMAM
News Sentiment

0.00

0.44

Average
Medical
News Sentiment

AMAM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMAM Articles
This Week

0

1

AMAM Articles
Average Week

Get Ambrx Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NYSE:AMAM) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners